
Botanix Pharmaceuticals Ltd
ASX:BOT

Intrinsic Value
The intrinsic value of one
BOT
stock under the Base Case scenario is
1.71
AUD.
Compared to the current market price of 0.3 AUD,
Botanix Pharmaceuticals Ltd
is
Undervalued by 82%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Botanix Pharmaceuticals Ltd
Fundamental Analysis

A delay or failure in Botanix’s clinical trials for its leading synthetic cannabinoid therapies would significantly undermine investor confidence, given that the company’s core revenue potential relies on successful product approvals for conditions like acne and dermatitis.
Botanix’s proprietary Permetrex technology, designed to enhance the skin penetration of its synthetic cannabinoid formulations, provides a potential competitive advantage in drug delivery and differentiation from other dermatology players.

Revenue & Expenses Breakdown
Botanix Pharmaceuticals Ltd
Balance Sheet Decomposition
Botanix Pharmaceuticals Ltd
Current Assets | 67.8m |
Cash & Short-Term Investments | 48.4m |
Receivables | 799.5k |
Other Current Assets | 18.6m |
Non-Current Assets | 31.7m |
PP&E | 925.7k |
Intangibles | 30.7m |
Free Cash Flow Analysis
Botanix Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Botanix Pharmaceuticals Ltd
Revenue
|
569.6k
AUD
|
Cost of Revenue
|
-1.3m
AUD
|
Gross Profit
|
-724.9k
AUD
|
Operating Expenses
|
-39.7m
AUD
|
Operating Income
|
-40.4m
AUD
|
Other Expenses
|
1.1m
AUD
|
Net Income
|
-39.3m
AUD
|
BOT Profitability Score
Profitability Due Diligence
Botanix Pharmaceuticals Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Score
Botanix Pharmaceuticals Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
BOT Solvency Score
Solvency Due Diligence
Botanix Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Score
Botanix Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BOT Price Targets Summary
Botanix Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
BOT
is 1.28 AUD
with a low forecast of 0.51 AUD and a high forecast of 2.1 AUD.
Dividends
Current shareholder yield for BOT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BOT
stock under the Base Case scenario is
1.71
AUD.
Compared to the current market price of 0.3 AUD,
Botanix Pharmaceuticals Ltd
is
Undervalued by 82%.